Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 631-639

  Petta, Salvatore ^a   Camma, Calogero ^a,b   Di Marco, Vito ^a   Cabibi, Daniela ^a   Ciminnisi, Stefania ^a   Caldorella, Rosalia ^a   Licata, Anna ^a   Massenti, Maria Fatima ^a   Marchesini, Giulio ^c   Craxi, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RELAPSE; SEX DIFFERENCE; STEATOSIS; WAIST CIRCUMFERENCE;

ANTIVIRAL AGENTS; BODY MASS INDEX; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 69849109303     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42:987-1000.
2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194.
3. Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43:64-71.
4. Petta S, Cammà C, Di Marco V, et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with HCV genotype 1. Hepatology 2008; 48:28-37.
5. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125]:1695-1704.
6. Svegliati-Baroni G, Bugianesi E, Bousheral T, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007; 56:1296-1301.
7. Petta S, Cammà C, Di Marco V, et al. Insulin resistance, and diabetes, increase fibrosis in the liver of patients with HCV genotype 1 infection. Am J Gastroenterol 2008; 103:1136-1144.
8. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rare to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641.
9. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48:28-34.
10. Eckel RH, Grundy SM, Zimmer PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428.
11. Wang CS, Wang ST, Yao WJ, et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007; 166:196-203.
12. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38:50-56.
13. Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005; 100:48-55.
14. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2003; 90:3498-3504.
15. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4,serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134:416-423.
16. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic heratitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44:1648-1955.
17. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126;840-848.
18. Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38:1384-1392.
19. Miyamoto H, Mochizuki K, Moriya K, et al. Involvement of the PA28γ-dependent pathway in insulin resistance induced by hepatitis C core protein. J Virol 2007; 81:1727-1735.
20. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RIJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48:721-727.
21. Simo R, Lecube A Genesca J, et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006; 29:2462-2466.
22. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178:457-465.
23. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102:570-576.
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23:S4-S19.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
26. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
27. Ikeda Y, Suchiro T, Nakamura T, et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001; 48:81-86.
28. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
29. EASL International Consensus Conference on Hepatitis C, Paris 26-27 February 1999, Consensus Statement. J Hepatol 1999; 31 Suppl 1:S3-S8.
30. SAS Technical Report. SAS/STAS software: changes & enhancement. Release 6.07; Cary, NC: SAS Institute, Inc. 1992.
31. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36:S237-S244.
32. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38:641-647.
33. Imano E, Kanda T, Ishigami Y, et al. Interferon induces insulin resistance in patients with-chronic active hepatitis C. J Hepatol 1998; 28:189-193.
34. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-7039.
35. Kaur S, Uddin S, Platania LC. The PI3′ kinase pathway in interferon signaling. J Interferon Cytokine Res 2005; 25:780-787.
36. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
37. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus glacebo for 48 weeks for treatment of chronic infection wit hepatitis C virus. Lancet 1998; 352:1426-1432.
38. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
39. Nelson HD. Menopause. Lancet 2008; 371:760-770.
40. Karpuzoglu-Sahin E, Hissong BD, Ahmed SA. Interferon-γ levels are uprTulated by 17-β-estradiol and diethylstilbestrol. J Reprod Immunol 2001;52:113-127.
41. Karpuzoglu E, Fenaux JB, Phillips RA, et al. Estrogen up-regulates inducible nitric oxide synthase, nitric oxide, and cyclooxygenase-2 in splenocytes activated with T cell stimulants: role of interferon-γ. Endocrinology 2006; 147:662-671.
42. Gourdy P, Araujo LM, Garmy-Susini B, et al. Relevance of sexual dimorphism to regulatory T cells: estradiol promotes IFN-γ production by invariant natural killer T cells. Blood 2005; 105:2415-21420.
43. Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44:335-340.